Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   201 Trials   201 Trials   5515 News 


«12...2021222324252627282930...6970»
  • ||||||||||  Safety and efficacy of monoclonal antibodies and tyrosine kinase inhibitors in advanced breast carcinoma. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1271;    
    Both monoclonal antibodies and tyrosine kinase inhibitors show clinically significant benefits in advanced HER2 positive breast carcinoma. However, more evidence and randomized clinical trials are needed to further establish their role in this rapidly evolving field.MAR = Margetuximab, TRA = Trastuzumab, ZENO = Zenocutuzumab, PER = Pertuzumab, SOC = Standard of Care, NER = Neratinib, CAP = Capecitabine, LAP = Lapatinib, TUC = Tucatinib, POZ = Poziotinib, PbO = Placebo, F.N = Febrile Neutropenia, D = Diarrhea, PPES = Palmar-Plantar Erythrodysesthesia, A = Anemia, N = Neutropenia.
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Tukysa (tucatinib) / Seagen
    Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress). (Available On Demand; 486a) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1197;    
    P2
    Tucatinib is approved in the US for use in combination with trastuzumab and capecitabine in adult patients with HER2+ metastatic breast cancer (MBC), with and without brain metastases, who have received ≥1 prior anti–HER2-based regimens in the metastatic setting...Patients must have prior treatment with a taxane and trastuzumab (with or without pertuzumab) in the LA/M setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including a taxane and trastuzumab (with or without pertuzumab)...Efficacy and safety will be summarized with descriptive statistics. Enrollment in the US began in late 2020.
  • ||||||||||  A166 / Sichuan Kelun Pharma
    Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors. (Available On Demand; 415) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1124;    
    Median age was 53.5 years (range 26-71), 58 pts (100%) had prior HER2-targeted therapy with the median lines of 4, including 100% received trastuzumab ± pertuzumab, 94.8% received anti-HER2 TKIs, and 20.7% received anti-HER2 ADCs in the metastatic setting. The previously demonstrated preliminary clinical benefit of A166-ADC was maintained with no new safety signals, which demonstrated manageable toxicity and encouraging anti-tumor activity in heavily pretreated HER2-positive metastatic breast cancer patients.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal, HEOR:  Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer. (Pubmed Central) -  Apr 26, 2022   
    When the price of pertuzumab and trastuzumab were both reduced by more than 71%, the incremental cost-effectiveness ratio decreased below $100 000 per QALY. The findings of this population-based study suggest that pertuzumab may increase survival for patients with metastatic breast cancer but would not be considered cost-effective, even after 100% price reduction, under conventional thresholds.
  • ||||||||||  Neoadjuvant and Adjuvant Treatment for HER2-positive Breast Cancer (RM 3(Walker Hall 1)) -  Apr 22, 2022 - Abstract #GBCC2022GBCC_51;    
    Extended therapy with neratinib could be considered for patients who have completed 1 year of trastuzumab when it is an ER+HER2+high risk disease...The introduction of new antibody drug conjugate (ADC) such as trastuzumab deruxtecan in metastatic breast cancer is shaking the definition of HER2 positivity as it is showing not only groundbreaking efficacy in HER2 positive BC but also outstanding data even in low HER2 BC (IHC 1 or 2 with ISH negative) which is previously considered HER2 negative disease. According to the results of trials in eBC with trastuzumab deruxtecan, all the aforementioned paradigms of treatments would be affected in near future.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    A New Promise: HER2 Vaccines and Immunotherapy (RM 1(Vista 1+2)) -  Apr 22, 2022 - Abstract #GBCC2022GBCC_24;    
    Moreover, to overcome HLA restriction and short-lived immune response, large fragments of HER2 protein vaccines as protein or DNA vaccines are under active investigation. Also, combinations with 2 major immune checkpoint inhibitors (ICI; anti-PD1/PD-L1 and anti-CTLA4) are important areas of investigation and early data showed a potential to direct immune response after harnessing the immune system by the ICIs.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trials of Surgery in Japan (RM 5(Art Hall)) -  Apr 22, 2022 - Abstract #GBCC2022GBCC_18;    
    First patient enrollment was done in November, 2019 and 206 pts have been enrolled as of February 28, 2022. Patient enrollment is expected to be completed by November, 2022, and primary endpoint is planned to be published in early 2026.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Journal:  ASH1L may contribute to the risk of Tourette syndrome: Combination of family-based analysis and case-control study. (Pubmed Central) -  Apr 21, 2022   
    Although the median OS in both the pertuzumab and control groups were shorter in this study than those observed in the CLEOPATRA trial, there appears to be a similar significant OS benefit with pertuzumab in the real-world setting. Our study suggests that ASH1L may contribute to TS susceptibility in the Han Chinese population and involved in TS development as a risk factor.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
    Enrollment open:  Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment (clinicaltrials.gov) -  Apr 20, 2022   
    P2,  N=50, Recruiting, 
    Cell cycle regulation is modified in endocrine-resistant breast cancer cells, and seliciclib is effective in both endocrine-sensitive and resistant diseases. Not yet recruiting --> Recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion date, Trial primary completion date:  A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging (clinicaltrials.gov) -  Apr 18, 2022   
    P2,  N=134, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2023
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Review, Journal:  Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes. (Pubmed Central) -  Apr 15, 2022   
    She underwent seven months of dual anti-HER2 blockade before relapsing cerebrally. Our results suggest that the sequential combination therapy with Trastuzumab, Pertuzumab and Paclitaxel presented in this study, associated with a healthy lifestyle, may be a good management for recurrent HER2-positive breast cancer with pulmonary visceral crisis and severe liver dysfunction.
  • ||||||||||  Journal:  Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. (Pubmed Central) -  Apr 13, 2022   
    Immune checkpoint inhibitors (anti-PD-1/ anti-CTLA-4) and anti-cancer vaccines (NeuVax, Muc-1, AVX901, INO-1400 and CEA), either alone or in combination with other therapies have created new paradigm in therapeutic world. In this review, we highlighted the current immunotherapeutic aspects and their ongoing trials towards the better treatment regimen for BC.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Perjeta (pertuzumab) / Roche
    Review, Journal:  Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. (Pubmed Central) -  Apr 12, 2022   
    In summary, our study identifies classical complement activation as a significant anti-tumor MOA for T+P therapy that may be functionally enhanced to augment therapeutic efficacy in the clinic. These benefits and risks inform treatment decisions for individuals and recommendations for groups of women.